Aurigene reports promising phase-1 data for its CAR-T therapy against myeloma

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with multiple myeloma. All patients achieved clinical response, with no high-grade safety events reported. The Indian drug regulator has approved the commencement of a phase-2 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hhc72ZO
via IFTTT